Axsome Therapeutics' Pioneering R&D Day
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical leader in neurology and psychiatry, hosted their Frontiers in Brain Health R&D Day to explore groundbreaking developments in their central nervous system (CNS) pipeline. This event underscored their commitment to advancing treatments for conditions like Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation.
Industry-Leading CNS Pipeline Review
During the event, expert clinicians and key opinion leaders presented insightful data analyses that highlighted the current landscape of CNS treatment. Axsome's diverse pipeline includes late-stage clinical trials aimed at addressing significant unmet needs for millions of patients.
Key Expert Presentations
Several renowned specialists articulated their thoughts on the conditions targeted by Axsome's promising therapies. Here are some key highlights from their discussions:
- Dr. Andrea Chadwick: An overview of fibromyalgia, including completed Phase 2 and Phase 3 clinical trials of AXS-14.
- Dr. Jeffrey Cummings: Insights into Alzheimer's disease agitation and results from the ADVANCE and ACCORD Phase 3 trials of AXS-05.
- Dr. Andrew Cutler: Discussion of ADHD and major depressive disorder (MDD), including outcomes from the FOCUS and PARADIGM Phase 3 trials of solriamfetol.
- Dr. Susan McElroy: An exploration into binge eating disorder and its implications.
- Dr. Stewart J. Tepper: Review of migraine treatments and data from the MOMENTUM and INTERCEPT Phase 3 trials.
- Dr. Michael Thorpy: Presentation on narcolepsy and the clinical trial program regarding AXS-12.
Engagement with the Audience
The management team at Axsome Therapeutics engaged with event attendees, addressing their queries regarding the innovative treatments discussed throughout this significant day. This interaction fosters a community of interest among investors and those affected by CNS disorders.
Webcast Information
This R&D Day was tailored for institutional investors and sell-side analysts. Axsome made the event accessible through a live webcast, which included a replay available on their "Webcasts & Presentations" page within the Investor section of the Axsome website.
About Axsome Therapeutics
Axsome Therapeutics is dedicated to delivering groundbreaking solutions for treating CNS disorders. Their portfolio consists of FDA-approved medications addressing various conditions including major depressive disorder, narcolepsy-related sleepiness, and migraine. Additionally, their late-stage developmental programs aim to provide solutions for neurological and psychiatric issues impacting millions.
Contact Information for Inquiries
Investors:
Mark Jacobson
Chief Operating Officer
(212) 332-3243
mjacobson@axsome.com
Media:
Darren Opland
Director, Corporate Communications
(929) 837-1065
dopland@axsome.com
Frequently Asked Questions
What is Axsome Therapeutics focused on?
Axsome Therapeutics specializes in developing treatments for various central nervous system disorders.
What conditions are included in Axsome's pipeline?
The pipeline targets conditions such as Alzheimer's, fibromyalgia, narcolepsy, and ADHD among others.
Where can I access the webcast of the R&D Day?
The webcast is available on the "Webcasts & Presentations" page on Axsome's official website.
Who are the key experts presenting at the event?
Experts from various prestigious institutions presented at the event, contributing valuable insights into CNS disorders.
How can I contact Axsome Therapeutics for investment questions?
You can reach out to Mark Jacobson, the COO of Axsome, via email for any investor inquiries.
